Soligenix Approaches Pivotal 2026 With Clinical Trial Advancements
Soligenix is advancing towards clinical milestones in 2026, with its Phase 3 HyBryte trial for cutaneous T-cell lymphoma (CTCL) and the progression of SGX945 for Behçet's disease. Multiple clinical catalysts are anticipated.
Topics
Developing
- 865d Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
- 865d Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
- 865d Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est.
- 865d Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium.
Sources · 7 independent
Source Alpha
Source Bravo
Source Charlie
Source Delta
Source Echo
Source Foxtrot
Source Golf
Unlock the full story
Get a Pro subscription or above to see the live story progression and the full list of independent sources confirming each event as they happen.
Log in to upgrade